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Therapeutic Interference: A Step 
Closer for Pachyonychia Congenita?
Elizabeth L. Rugg1
The identification of mutations in keratin genes as the cause of several inher-
ited skin disorders raised the possibility that molecular-based therapies might 
be developed to treat these conditions. In this issue, Smith et al. (2007) have 
identified small interfering RNAs that specifically and potently silence keratin 
6a expression. These molecules have great promise as therapeutic agents for the 
treatment of pachyonychia congenita.
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RNA interference (RNAi) is a highly 
evolutionally conserved process that is 
used by cells to selectively regulate and 
silence gene expression. It is widely 
used as an experimental tool, and it is 
increasingly apparent that RNAi also 
has great potential as a therapeutic strate-
gy for treating many human disorders, 
including genetic diseases, viral infec-
tions, and cancer (Ryther et al., 2005; 
Akhtar and Benter, 2007). Synthetic 
small inhibitory RNAs (siRNAs) can be 
introduced into the cell, where they 
are incorporated into the RNA-induced 
silencing complex (RISC), leading to 
degradation of mRNA with sequence 
complementary to the siRNA (Kim and 
Rossi, 2007). Clinical trials are already 
in progress to evaluate siRNA for the 
treatment of macular degeneration and 
lung disease. Although these trials are 
not complete, early reports suggest that 
the siRNAs are effective and without 
side effects (Akhtar and Benter, 2007).
Keratin disorders are a group of 
inherited conditions caused by muta-
tions in genes that encode proteins of 
the keratin intermediate filament cyto-
skeleton. Most of these conditions result 
from single-nucleotide substitutions in 
one copy of a keratin gene, leading to 
amino acid changes that affect kera-
tin filament formation. This presents a 
challenge for the development of thera-
pies for keratin disorders because they 
must reduce or eliminate the effects of 
the mutant protein. Currently, RNAi 
is the most promising strategy for spe-
cifically knocking down expression of 
disease-causing genes. One of the first 
steps in drug development is the identi-
fication of potent molecules with target 
specificity and lack of toxicity. Smith et 
al. (2007, this issue) identified siRNAs 
that are active in the picomolar range, 
which brings a step closer the prospect 
of a therapy for one keratin disorder, 
pachyonychia congenita (PC).
PC is an autosomal dominant con-
dition characterized by palmoplantar 
keratoderma and nail dystrophy, which 
may be accompanied by epidermal 
cysts and oral lesions. For patients the 
most painful feature of this condition is 
plantar keratoderma (Leachman et al., 
2005). PC is caused by mutations in 
keratins K6a, K6b, K16, and K17. Rather 
than target siRNA to a specific gene 
mutation, Smith and colleagues (2007) 
exploited the overlapping expression of 
a pattern of keratins K6a and K6b and 
targeted siRNAs to the 3′ UTR of the 
keratin 6a gene. This is a very attractive 
strategy because a single siRNA can 
be used to ablate K6a expression irre-
spective of mutation and gets around 
the need to develop mutation-specific 
molecules. Loss of K6a expression 
is without serious consequences in 
mice (Wojcik et al., 2000). It is reason-
able to assume that ablation of K6a in 
humans will be without serious side 
effects, particularly if siRNA treatment 
is limited to lesion sites such as areas 
of keratoderma on the sole of the foot. 
Further support for the lack of effect of 
reducing K6a expression comes from 
a recent report on variation of gene 
copy numbers in the human genome. 
Around 3% of the population is het-
erozygous for a deletion that includes 
the genes for both K6a and K6b (Wong 
et al., 2007). Smith et al. (2007) specu-
late that approximately 75,000 indi-
viduals in the United States may be null 
for both K6a and K6b expression. The 
identification of such individuals and 
confirmation that they are indeed with-
out a phenotype would provide incon-
trovertible evidence that silencing of K6 
expression is a viable therapeutic strate-
gy for the treatment of PC. In addition, 
it would indicate important differences 
between humans and mice because 
loss of K6a and K6b in mice results in 
a severe oral phenotype and failure to 
thrive (Wong et al., 2000).
Although there is considerable 
redundancy in the expression of K6 
genes, this is not true for all keratins. 
For example, ablation of keratin 14 
expression causes the blistering dis-
order epidermolysis bullosa simplex, 
and, although there may be compensa-
tion in some tissues by K15, the phe-
notype is broadly similar to that caused 
by dominant negative K14 mutations 
(Chan et al., 1994; Rugg et al., 1994). 
It is theoretically feasible to develop 
mutation-specific siRNAs; however, 
this may not be practical given the 
large number of different keratin muta-
tions and the expense associated with 
drug development and testing. An 
alternative, indirect approach would 
be to target siRNAs to polymorphisms 
that would result in allele-specific 
mRNA degradation. However, caution 
is needed with this approach because 
the resulting haploinsufficiency may 
have unwanted side effects. For exam-
ple, haploinsufficiency in keratin 5 
1Department of Dermatology, University of California, Irvine, Irvine, California, USA
Correspondence: Dr Elizabeth L. Rugg, Department of Dermatology, C340 Medical Sciences 1,  
University of California, Irvine, Irvine, California 92697. E-mail: erugg@uci.edu
|
Small interfering 
RNAs have promise 
for the treatment 
of pachyonychia 
congenita.
COMMENTARY
8 Journal of Investigative Dermatology (2008), Volume 128
expression is associated with Dowling–
Degos disease (Betz et al., 2006). 
The extent to which reduced levels of 
expression of other keratins, such as 
the other PC-associated proteins K16 
and K17, would lead to disease pheno-
types is not known.
SiRNAs offer the promise of a “magic 
bullet” for treating many genetic disor-
ders, but there are still some potential 
problems with their use as therapeu-
tic agents. The target specificity must 
be validated for each siRNA and off-
target effects must be eliminated or 
minimized. This may not be an easy 
problem to address because siRNAs, 
by necessity, are sequence specific 
and therefore may be ineffective or 
have different off-target effects in ani-
mal and humans. Potential side effects 
include activation of the interferon sys-
tem, knockdown of unrelated gene tar-
gets due to sequence similarities, and 
saturation of the RISC, which interferes 
with processing of endogenous micro 
RNAs needed for normal cell func-
tion (Ryther et al., 2005; Barik, 2006). 
Evidence to date suggests that such 
problems can be overcome by avoid-
ing the use of viral expression vectors 
and taking care in the design of highly 
specific synthetic siRNA, as is the case 
in the report by Smith et al. (2007). 
Finally, it is not known whether there 
are long-term effects of siRNA treat-
ment. For such molecules to be thera-
peutically effective, they will need 
long-term administration.
Perhaps the biggest hurdle to be 
overcome is that of delivery. siRNAs 
must cross cell membranes and be 
incorporated into the RISC. Although 
the skin offers a large and accessible 
target, it is also a barrier. Wang et al. 
(2007) have demonstrated that siRNA 
can be delivered by injection to kera-
tinocytes in the mouse foot pad, and 
Smith et al. (2007), using this method 
of delivery, showed that that K6a gene 
expression can be specifically inhibited 
by siRNAs in this model system (Wang 
et al., 2007). Whether this will prove 
to be a viable method for treatment of 
PC patients will depend on a number of 
factors, including how many injections 
are needed and how often they will 
need to be repeated to maintain gene 
silencing. Several other methods have 
been shown to be capable of deliver-
ing DNA to keratinocytes, including 
ballistic delivery using a gene gun, 
ultrasound and iontophoresis, and topi-
cal application. It remains to be seen 
which, if any, of these methods will be 
most effective and tolerated in patients.
RNAi holds great promise as a therapy 
for genetic disorders and is particularly 
attractive for targeting skin disorders. The 
accessibility of the skin, which allows 
restricted application, makes it an ideal 
system for testing the effectiveness of 
siRNA and minimizing the likelihood of 
generalized systemic effects. It remains 
to be established whether RNAi will turn 
out to be a viable method for treating PC 
or other keratin disorders. The report by 
Smith et al. (2007) brings this prospect 
significantly closer.
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